Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JUND drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JUND Recombinant Protein (bZIP Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for DNA-binding and PPI assays. |
View JUND Products |
| Gene Delivery | JUND Promise-ORF / Lentivirus Full-length ORF for stable cell lines and AP-1 reporter assay development. |
View JUND Products |
| Benchmark Ab | Anti-JUND Recombinant Antibody High-affinity positive control for ChIP, Western Blot, and ELISA validation. |
View JUND Products |
| Validator | JUND siRNA Set For target knockdown verification and functional rescue assays. |
View JUND Products |
| Related Target A | JUN (c-Jun) Key heterodimerization partner in the AP-1 transcription factor complex. |
View JUN Products |
| Related Target B | FOS (c-Fos) Co-mediator of AP-1 transcriptional activity in inflammatory and oncogenic pathways. |
View FOS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein Aggregation & Instability | Highly optimized expression constructs representing the stable bZIP domain, sequence verified, and purified under native conditions. |
| Subfamily Off-Target Screening | Homolog panel including c-Jun, JunB, and c-Fos proteins strictly verified by mass spectrometry to evaluate target selectivity. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies and validated positive controls included in the catalog. |
| False Positives in PPI Screening | Sequence-verified wild-type and mutant control proteins paired with validated siRNA sets for precise target specificity checks. |
Live JUND R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JUND therapeutics is intensifying, with major players shifting focus from traditional systemic cytostatic agents to targeted transcriptional modulators. As first-generation small-molecule inhibitors of the AP-1 complex reach preclinical and early clinical milestones, the next wave of R&D is targeting JUND-specific protein-protein interactions (PPI) and targeted protein degradation (PROTACs). By selectively blocking JUND dimerization with FOS/JUN partners or inducing its degradation, researchers aim to halt fibrotic progression in NASH/MASH and reverse immunosuppressive microenvironments in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | NASH/MASH, Renal Fibrosis, Solid Tumors | Dimerization Inhibition Assay (Need high-purity JUND and FOS/JUN proteins) |
| PROTAC / Degrader | Targeted Therapeutics Specialists | Prostate Cancer, TNBC | Ubiquitination & Degradation Profiling (Need native-glycosylation HEK293 or E. coli expressed target proteins) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Pioneers | Hypertrophic Scars, Fibrotic Diseases | In vitro Knockdown Validation (Need validated JUND siRNA sets and transfection-ready Lentivirus) |